Published in Pharmacogenomics on January 01, 2013
Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol (2007) 2.27
Primary aldosteronism in hypertensive patients: clinical implications and target therapy. Eur J Clin Invest (2014) 1.99
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res Treat (2008) 1.82
Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection. Crit Care (2010) 1.55
Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol (2004) 1.48
Total thyroidectomy for the treatment of thyroid diseases in an endemic area. South Med J (2006) 1.46
New technology-based innovation changes surgical practice and research direction in solid cancers. Surg Endosc (2010) 1.39
Self-locking first stitch in suture reinforcement of the laparoscopic gastric sleeve. Obes Surg (2013) 1.20
The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev (2004) 1.18
From next-generation sequencing to nanopore sequencing technology: paving the way to personalized genomic medicine. Expert Rev Med Devices (2013) 1.16
Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol (2009) 1.14
Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer (2009) 1.11
Unusual site of recurrent musculoskeletal hydatid cyst: case report and brief review of the literature. World J Gastroenterol (2006) 1.09
Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn (2009) 1.05
EZH2 is regulated by ERK/AKT and targets integrin alpha2 gene to control Epithelial-Mesenchymal Transition and anoikis in colon cancer cells. Int J Biochem Cell Biol (2012) 1.05
Laparoscopic ventral hernia repair: pros and cons compared with open hernia repair. JSLS (2008) 1.05
Application of the pedicled anterolateral thigh flap to defects from the pelvis to the knee. Microsurgery (2006) 1.04
Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn (2009) 1.04
Incisional hernioplasty with extraperitoneal onlay polyester mesh. Am Surg (2004) 1.03
Predictors of survival in stage IV metastatic colorectal cancer. Anticancer Res (2010) 1.02
Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. Mod Pathol (2012) 1.01
Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med (2007) 1.01
Delorme's procedure revisited for an incarcerated transverse loop colostomy prolapse repair. Am Surg (2013) 1.00
Contraindications of sentinel lymph node biopsy: are there any really? World J Surg Oncol (2007) 1.00
Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg (2009) 0.99
Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol (2009) 0.99
Reinforcing the staple line during laparoscopic sleeve gastrectomy: prospective randomized clinical study comparing two different techniques. Preliminary results. Obes Surg (2012) 0.99
Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther (2006) 0.99
Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics (2010) 0.99
Impact of spleen preservation in patients with gastric cancer. Anticancer Res (2005) 0.99
Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med (2010) 0.99
CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol (2009) 0.99
Genome-wide association studies: how predictable is a person's cancer risk? Expert Rev Anticancer Ther (2009) 0.98
Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn (2009) 0.97
Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol (2008) 0.96
Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg (2009) 0.95
Serum adiponectin levels and tissue expression of adiponectin receptors are associated with risk, stage, and grade of colorectal cancer. Metabolism (2011) 0.95
Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther (2005) 0.95
Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg (2009) 0.94
Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Devices (2010) 0.93
Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn (2010) 0.92
Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol (2009) 0.92
Association of aberrant DNA methylation with clinicopathological features in breast cancer. Oncol Rep (2011) 0.92
Morbid obesity and sleeve gastrectomy: how does it work? Obes Surg (2010) 0.92
Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg (2008) 0.92
C-reactive protein, white blood cells, and neutrophils as early predictors of postoperative complications in patients undergoing laparoscopic sleeve gastrectomy. Surg Endosc (2012) 0.91
Clinical implications of sleeve gastrectomy as a source of spleen infarction or ischemia. Obes Surg (2011) 0.91
The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol (2007) 0.91
Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol (2009) 0.90
Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn (2010) 0.90
Association of the miR-146aC>G, miR-149T>C, and miR-196a2T>C polymorphisms with gastric cancer risk and survival in the Greek population. Mol Biol Rep (2013) 0.90
Routine abdominal drains after laparoscopic sleeve gastrectomy: a retrospective review of 353 patients. Obes Surg (2011) 0.89
Radiation therapy for breast cancer. N Engl J Med (2009) 0.89
Long-term plasma ghrelin and leptin modulation after sleeve gastrectomy in Wistar rats in comparison with gastric tissue ghrelin expression. Obes Surg (2011) 0.89
Cancer genome explosion and systems biology: impact on surgical oncology? Ann Surg Oncol (2011) 0.89
Laparoscopic surgery for gastric cancer: comparative-effectiveness research and future trends. Expert Rev Anticancer Ther (2010) 0.89
Systems medicine: a real approach for future personalized oncology? Pharmacogenomics (2010) 0.89
Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol (2002) 0.88
Breast cancer nodal metastasis correlates with tumour and lymph node methylation profiles of Caveolin-1 and CXCR4. Clin Exp Metastasis (2014) 0.88
Translating epigenetics into an anticancer drug pipeline for solid tumors. Expert Rev Med Devices (2011) 0.88
Networks medicine: from reductionism to evidence of complex dynamic biomolecular interactions. Pharmacogenomics (2011) 0.88
Coexistence of tumor-induced osteomalacia and primary hyperparathyroidism. Endocr Pract (2011) 0.87
Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer? Surg Endosc (2008) 0.87
Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Rev Med Devices (2011) 0.87
From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther (2010) 0.87
Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther (2009) 0.86
Is early laparoscopic cholecystectomy for acute cholecystitis preferable to delayed surgery?: Best evidence topic (BET). Int J Surg (2012) 0.86
Postoperative pulmonary function after open abdominal aortic aneurysm repair in patients with chronic obstructive pulmonary disease: epidural versus intravenous analgesia. Ann Vasc Surg (2011) 0.86
Esophageal Doppler (ODM II) improves intraoperative hemodynamic monitoring during laparoscopic surgery. Surg Laparosc Endosc Percutan Tech (2005) 0.86
Tumor suppressor PTEN in breast cancer: heterozygosity, mutations and protein expression. Anticancer Res (2014) 0.86
Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J Clin Oncol (2010) 0.86
Linking contralateral breast cancer with genetics. Radiother Oncol (2008) 0.85
Isolated tumor cells in breast cancer. N Engl J Med (2009) 0.85
Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension. J Clin Endocrinol Metab (2013) 0.85
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2008) 0.84
Breast-cancer stromal cells with TP53 mutations. N Engl J Med (2008) 0.84
Localized peripancreatic plasma cell Castleman disease. Am J Surg (2010) 0.84
Role of the hematopoietic cytokines SCF, IL-3, GM-CSF and M-CSF in the diagnosis of pancreatic and ampullary cancer. Int J Biol Markers (2012) 0.84
Do anastomotic leaks impair postoperative health-related quality of life after rectal cancer surgery? A case-matched study. Dis Colon Rectum (2014) 0.84
Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol (2002) 0.84
Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the "Gordian Knot"? Ann Surg Oncol (2008) 0.83
Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol (2002) 0.83
'Big' science: genome regulatory networks and novel molecular tools to improve health. Expert Rev Mol Diagn (2011) 0.83
Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology. World J Gastroenterol (2012) 0.83
Genome diagnostics: next-generation sequencing, new genome-wide association studies and clinical challenges. Expert Rev Mol Diagn (2011) 0.83
Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol (2002) 0.83
Circulating tumor DNA: new horizons for improving cancer treatment. Future Oncol (2015) 0.83
Genomics and challenges toward personalized breast cancer local control. J Clin Oncol (2008) 0.82
Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol (2002) 0.82
Prospective comparative study of the efficacy of staple-line reinforcement in laparoscopic sleeve gastrectomy. Surg Endosc (2011) 0.82
Immunohistochemical expression of P15 (INK4B) and SMAD4 in advanced gastric cancer. Anticancer Res (2008) 0.82
Current advantages in the application of proteomics in inflammatory bowel disease. Dig Dis Sci (2012) 0.82
Clinical relevance of cancer genome sequencing. World J Gastroenterol (2013) 0.82